What was Ibnsina Pharma's net profit in 2025?

Ibnsina Pharma's net profit in 2025 was 952 million EGP, up 54.9% from 615 million EGP in 2024. Source: annual statements 2025.

What were Ibnsina Pharma's total assets and shareholders' equity in 2025?

Total assets at the end of 2025 were 36.21 billion EGP, and shareholders' equity 2.78 billion EGP. Source: annual statements 2025.

Was Ibnsina Pharma's operating cash flow positive in 2025?

Operating cash flow in 2025 was negative at 71.06 million EGP. Source: annual statements 2025.

EGX·Health Care & Pharmaceuticals

Ibnsina Pharma

ISPH

Fiscal year starts in January · currency EGP · latest: Q2 2026

Next results: Q3 2026 — expected around 16 November 2026published last year on 16 November 2025Results calendar ←

9.45EGP+3.39% today1w −6.0%1m −21.8%delayed · 3 November

Net profit · 2025

952million

▲ 54.9% vs 2024

Total assets · 2025

36.21billion

▲ 26.4% vs 2024

Shareholders' equity · 2025

2.78billion

▲ 37.1% vs 2024

Operating cash flow · 2025

−71.06million

▲ 93.5% vs 2024

Key facts

Source: annual statements 2025

Ibnsina Pharma's net profit in 2025 was 952 million EGP, up 54.9% from 615 million EGP in 2024.
Total assets at the end of 2025 were 36.21 billion EGP, and shareholders' equity 2.78 billion EGP.
Operating cash flow in 2025 was negative at 71.06 million EGP.

Ibnsina Pharma's Q3 2026 results are expected around 16 November — we email you the day they land

One email on the day, no account, and a one-click stop in the email itself.

orFollow on TelegramEvery result as it lands, in the @askborsa channel

By subscribing you agree to receive these alerts only. Privacy policy

AI summary

Preparing a summary of the latest results…

Ask about Ibnsina Pharma

How much did Ibnsina Pharma's net profit grow last year?What were total assets and shareholders' equity in the latest annual balance sheet?Was operating cash flow positive in the last three years?Type your question…Ask

3 free questions a day after signing up. With Google, no password.

Annual net profit last 5 years

Net profit

315million

173million

214million

615million

952million

20212022202320242025

Summarised financial statements

Excel · Pro

Swipe the table to see the other years.

Item · EGP20212022202320242025

Income statement

Net profit315 million173 million214 million615 million952 million

Gross profit1.63 billion1.62 billion2.63 billion4.53 billion6.48 billion

Total assets11.28 billion12.86 billion18.55 billion28.64 billion36.21 billion

Total liabilities9.83 billion11.6 billion17.1 billion26.61 billion33.43 billion

Shareholders' equity1.45 billion1.26 billion1.45 billion2.03 billion2.78 billion

Total liabilities and equity11.28 billion12.86 billion18.55 billion28.64 billion36.21 billion

Operating cash flow-340 million362 million126 million-1.1 billion-71.06 million

Investing cash flow-143 million-15.61 million-280 million-260 million-648 million

Financing cash flow681 million1.09 billion744 million891 million804 million

Net change in cash94.99 million72.67 million590 million-295 million84.33 million

With Google or your email, no password.

Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. What does this line mean?

Results by period

One page per period: the figures against the same period a year earlier, and the official report.

Fiscal year 2025 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Fiscal year 2024 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Fiscal year 2023 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Fiscal year 2022 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Fiscal year 2021

Ibnsina Pharma

Key facts

Ibnsina Pharma's Q3 2026 results are expected around 16 November — we email you the day they land

Summarised financial statements

Results by period

Financial reports (18)

Other companies in Health Care & Pharmaceuticals